|
시장보고서
상품코드
1741546
세계의 흡입 가능 약제 시장 : 약제 클래스별, 제품 유형별, 용도별, 유통 채널별, 지역별Global Inhalable Drugs Market, By Drug Class, By Product Type, By Application, By Distribution Channel, By Region |
||||||
세계의 흡입 가능 약제 시장은 2025년에는 400억 6,000만 달러로 추정되고, 2032년까지는 651억 7,000만 달러에 이를 것으로 예측되며, 2025-2032년 연평균 성장률(CAGR) 7.2%로 성장할 전망입니다.
| 보고 범위 | 보고서 세부정보 | ||
|---|---|---|---|
| 기준 연도 | 2024년 | 시장 규모(2025년) | 400억 6,000만 달러 |
| 실적 데이터 | 2020-2024년 | 예측 기간 | 2025-2032년 |
| 예측 기간 CAGR(2025-2032년) : | 7.20% | 예측 금액(2032년) | 651억 7,000만 달러 |
흡입 가능 약제는 폐를 경유하여 호흡기관으로부터 국소적으로 투여되어 신속한 치료 효과를 얻을 수 있는 의료 물질입니다. 천식, 만성 폐색성 폐질환, 낭포성 섬유증 등의 폐 질환의 치료에 특히 유효합니다. 폐는 소화관으로부터의 경구 투여와 비교하여 약물 흡수를 위한 거대한 표면적을 제공합니다. 흡입 가능 약제는 간 첫 회 통과 대사를 우회하기 때문에 폐 조직에 직접 약제를 빠르게 전달하여 전신 수준을 낮출 수 있습니다. 주요 장점으로는 경구약과 비교하여 몇 분 이내의 신속한 작용 발현, 저용량 투여, 부작용 경감 등을 들 수 있습니다. 인기 있는 흡입 가능 약제로는 알부테롤과 같은 천식과 만성 폐쇄성 폐질환용 기관지 확장제, 코르티코스테로이드, 분산성 항생제, 인슐린 등이 있습니다. 세계 폐질환의 증가에 따라 흡입 가능한 약제 시장은 향후에도 안정적인 성장이 전망되고 있습니다.
시장 역학 :
세계의 흡입 가능 약제 시장은 천식과 COPD 등 호흡기 질환의 세계 유병률 증가에 의해 견인되고 있습니다. 예를 들어 2023년 3월 16일 세계보건기구(WHO)에 따르면 만성폐쇄성폐질환(COPD)은 세계 3위의 사인이며 2021년에는 3억 명 이상이 천식에 이환되었고 COPD에서는 매년 300만 명 이상이 사망하고 있습니다. 오염 수준 증가 및 라이프 스타일 변화가 폐질환의 사례 수 증가에 기여하고 있습니다. 이 시장은 또한 호흡기에 직접적인 영향을 미치는 질환의 치료에 있어 흡입 가능 의약품의 뛰어난 치료 효과로부터도 이익을 얻고 있습니다. 정량흡입기(MDI)나 드라이 파우더 흡입기(DPI)등의 약물 전달 기기의 기술적 진보는, 신규 치료의 기회를 확대하고 있습니다. 그러나 흡입 가능 약제 개발과 생산에 관련된 높은 비용이 더 넓은 시장의 성장을 제한하고 있습니다. 게다가 폐 약물 전달 시스템의 임상 시험 및 제품 승인에 관한 엄격한 규제도 제약이 되고 있습니다. 그렇다고는 해도 선진적인 제제나 병용 요법에 관한 연구개발이 진행 중이기 때문에 예측 기간 중에 새로운 길이 열릴 가능성이 있습니다.
본 조사의 주요 특징
- 본 보고서는 세계의 흡입 가능 약제 시장을 상세하게 분석하고, 2024년을 기준연도로 한 예측 기간(2025-2032년) 시장 규모 및 복합 연간 성장률(CAGR)을 제공합니다.
- 또, 다양한 부문에 걸친 잠재적인 수익 기회를 해명해, 이 시장의 매력적인 투자 제안의 매트릭스에 대해서 설명하고 있습니다.
- 또한 시장 성장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업이 채용하는 경쟁 전략 등에 관한 주요 인사이트도 제공합니다.
- 기업 하이라이트, 제품 포트폴리오, 주요 하이라이트, 재무 실적, 전략 등의 파라미터에 근거해, 세계 흡입 가능 약제 시장의 주요 기업을 프로파일링하고 있습니다.
- 이 보고서의 인사이트를 통해 마케팅 담당자 및 기업 경영진이 미래의 제품 출시, 유형 업그레이드, 시장 확대, 마케팅 전술에 관한 정보에 근거한 의사 결정을 할 수 있게 합니다.
- 세계의 흡입 가능 약제 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통 업체, 신규 참가자, 재무 분석가 등이 업계의 다양한 이해 관계자에 대응하고 있습니다.
- 이해관계자는 세계의 흡입 가능 약제 시장을 분석할 때 사용되는 다양한 전략 매트릭스를 통해 의사결정을 용이하게 할 수 있습니다.
목차
제1장 조사 목적 및 전제조건
- 조사 목적
- 전제조건
- 약어
제2장 시장 전망
- 보고서 설명
- 시장 정의 및 범위
- 주요 요약
- 일관된 기회 지도(COM)
제3장 시장 역학, 규제 및 동향 분석
- 시장 역학
- 주요 하이라이트
- 규제 시나리오
- 최근 동향
- PEST 분석
- Porter's Five Forces 분석
- 합병, 인수 및 제휴
제4장 세계의 흡입 가능 약제 시장 : 코로나 바이러스(COVID-19) 팬데믹의 영향
- COVID-19 역학
- 공급측 및 수요측 분석
- 경제에 미치는 영향
제5장 세계의 흡입 가능 약제 시장 : 약제 클래스별(2020-2032년)
- 흡입 코르티코스테로이드
- 류코트리엔 조절제
- 장시간 작용형 β길항제(LABA)
- 장시간 작용형 무스카린 길항제(LAMA)
- 기타
제6장 세계의 흡입 가능 약제 시장 : 제품 유형별(2020-2032년)
- 에어로졸
- 건조 분말 제형
- 스프레이
- 기타
제7장 세계의 흡입 가능 약제 시장 : 용도별(2020-2032년)
- 호흡기 질환
- 천식
- 만성 폐색성 폐질환(COPD)
- 낭포성 섬유증
- 알레르기성 비염
- 기타
- 비호흡기 질환
제8장 세계의 흡입 가능 약제 시장 : 유통 채널별(2020-2032년)
- 병원 약국
- 소매 약국
- 온라인 약국
제9장 세계의 흡입 가능 약제 시장 : 지역별(2020-2032년)
- 북미
- 미국
- 캐나다
- 유럽
- 독일
- 영국
- 스페인
- 프랑스
- 이탈리아
- 러시아
- 기타 유럽
- 아시아태평양
- 중국
- 인도
- 일본
- 호주
- 한국
- ASEAN
- 기타 아시아태평양
- 라틴아메리카
- 브라질
- 아르헨티나
- 멕시코
- 기타 라틴아메리카
- 중동
- GCC 국가
- 이스라엘
- 기타 중동
- 아프리카
- 북아프리카
- 중앙 아프리카
- 남아프리카
제10장 경쟁 구도
- 기업 프로파일
- GSK plc.
- Mundipharma International.
- Boehringer Ingelheim International GmbH.
- Cipla Inc.
- AstraZeneca
- Sanofi
- Vectura Group Ltd.
- Viatris Inc.
- 3M Health Care
- Allied Healthcare Products, Inc.
- CareFusion Corporation
- GF Health Products, Inc.
- Merck &Co., Inc.
- Novartis AG
- Omron Healthcare, Inc.
- Glenmark Pharmaceuticals
- PARI Respiratory Equipment, Inc.
제11장 섹션
- 참조
- 조사 방법
- 출판사에 대해
Global Inhalable Drugs Market is estimated to be valued at USD 40.06 Bn in 2025 and is expected to reach USD 65.17 Bn by 2032, growing at a compound annual growth rate (CAGR) of 7.2% from 2025 to 2032.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 40.06 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 7.20% | 2032 Value Projection: | USD 65.17 Bn |
Inhalable drugs are medical substances that can be administered locally through the respiratory tract via the lung for rapid therapeutic effects. They are particularly effective for treating lung conditions such as asthma, chronic obstructive pulmonary disease and cystic fibrosis. The lung provides huge surface area for drug absorption as compared to oral administration through the gastrointestinal tract. Inhalable drugs bypass hepatic first-pass metabolism for faster delivery of medications directly to the lung tissues and lower systemic levels. Some key advantages include rapid onset of action within minutes, lower dosing, and reduced side effects as compared to oral medications. Popular inhalable drugs include bronchodilators for asthma and chronic obstructive pulmonary disease like albuterol, corticosteroids, dispersible antibiotics, and insulin. With rising lung diseases globally, the inhalable drugs market is expected to grow steadily in the future.
Market Dynamics:
Global inhalable drugs market is driven by the growing prevalence of respiratory diseases such as asthma and COPD worldwide. For instance, on March 16, 2023, according to the World Health Organization (WHO), chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide, and over 300 Mn people suffered from asthma in 2021, while over 3 Mn people die each year from COPD. Increasing pollution levels and changing lifestyles have contributed to the rising caseload of lung illnesses. The market also benefits from the superior therapeutic efficacy of inhalable drugs in treating conditions, affecting the respiratory tract directly. Technological advancements in drug delivery devices such as metered-dose inhalers (MDIs) and dry powder inhalers (DPIs) are expanding opportunities for novel therapies. However, high costs that are associated with development and production of inhalable drugs limit wider market growth. Additional constraints include stringent regulations around clinical trials and product approval for pulmonary drug delivery systems. Nevertheless, ongoing research and development (R&D) into advanced formulations and combination therapies could unlock new avenues over the forecast period.
Key features of the study:
- This report provides in-depth analysis of the global inhalable drugs market, and provides market size (US$ Bn) and compound annual growth rate (CAGR %) for the forecast period 2025-2032, considering 2024 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global inhalable drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include GSK plc, Mundipharma International., Boehringer Ingelheim International GmbH., Cipla Inc., AstraZeneca, Sanofi, Vectura Group Ltd, Viatris Inc, 3M Health Care, Allied Healthcare Products, Inc., CareFusion Corporation, GF Health Products, Inc., Merck & Co., Inc., Novartis AG, Omron Healthcare, Inc., Glenmark Pharmaceuticals and PARI Respiratory Equipment, Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- Global inhalable drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global inhalable drugs market
Detailed Segmentation:
- Global Inhalable Drugs Market, By Drug Class
- Inhaled Corticosteroids
- Leukotriene modifiers
- Long-acting beta agonists (LABAs)
- Long-acting muscarinic antagonists (LAMAs)
- Others
- Global Inhalable Drugs Market, By Product Type
- Aerosol
- Dry powder Formulation
- Spray
- Others
- Global Inhalable Drugs Market, By Application
- Respiratory Diseases
- Asthma
- Chronic Obstructive Pulmonary Disease (COPD)
- Cystic Fibrosis
- Allergic Rhinitis
- Others
- Non-respiratory Disease
- Global Inhalable Drugs Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Inhalable Drugs Market, By Region
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
- Company Profiles
- GSK plc.
- Mundipharma International.
- Boehringer Ingelheim International GmbH.
- Cipla Inc.
- AstraZeneca
- Sanofi
- Vectura Group Ltd.
- Viatris Inc.
- 3M Health Care
- Allied Healthcare Products, Inc.
- CareFusion Corporation
- GF Health Products, Inc.
- Merck & Co., Inc.
- Novartis AG
- Omron Healthcare, Inc.
- Glenmark Pharmaceuticals
- PARI Respiratory Equipment, Inc.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Inhalable Drugs Market, By Drug Class
- Global Inhalable Drugs Market, By Product Type
- Global Inhalable Drugs Market, By Application
- Global Inhalable Drugs Market, By Distribution Channel
- Global Inhalable Drugs Market, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Growing prevalence of respiratory diseases
- Risk of misuse of inhalable medicines
- Emergence of new drug delivery technologies
- Key Highlights
- Regulatory Scenario
- Recent Trends
- PEST Analysis
- PORTER's Analysis
- Mergers, Acquisitions, and Collaborations
4. Global Inhalable Drugs Market- Impact of Coronavirus (COVID-19) Pandemic
- COVID-19 Epidemiology
- Supply Side and Demand Side Analysis
- Economic Impact
5. Global Inhalable Drugs Market, By Drug Class, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Inhaled Corticosteroids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Leukotriene modifiers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Long-acting beta antagonists (LABAs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Long-acting muscarinic antagonists (LAMAs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
6. Global Inhalable Drugs Market, By Product Type, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Aerosol
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Dry powder Formulation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Spray
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
7. Global Inhalable Drugs Market, By Application, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Respiratory Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Asthma
- Chronic Obstructive Pulmonary Disease (COPD)
- Cystic Fibrosis
- Allergic Rhinitis
- Others
- Non-respiratory Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
8. Global Inhalable Drugs Market, By Distribution Channel, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
9. Global Inhalable Drugs Market, By Region, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, By Region, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, For Region, 2021 -2032
- Country Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020-2032,(US$ Bn)
- North Africa
- Central Africa
- South Africa
10. Competitive Landscape
- Company Profile
- GSK plc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Mundipharma International.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Boehringer Ingelheim International GmbH.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Cipla Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- AstraZeneca
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Sanofi
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Strategies
- Vectura Group Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Viatris Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- 3M Health Care
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Allied Healthcare Products, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- CareFusion Corporation
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- GF Health Products, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Omron Healthcare, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Glenmark Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- PARI Respiratory Equipment, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Analyst Views
11. Section
- Reference
- Research Methodology
- About us
